Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075445 | 0.86 | DAO (0.40) | HRH3VCPHTR4CARM1PRMT6 | |
| SCHEMBL20046477 | 0.85 | VCP (0.44) | HRH3VCP | |
| SCHEMBL102379 | 0.85 | HRH3 (0.42) | HRH3 | |
| SCHEMBL25075450 | 0.84 | GNAO1 (0.41) | HRH3VCPGNAO1 | |
| SCHEMBL12026484 | 0.84 | CYP1A2 (0.43) | HRH3VCP | |
| SCHEMBL25089687 | 0.83 | HRH3 (0.39) | HRH3VCP | |
| SCHEMBL21933949 | 0.81 | HRH3 (0.47) | HRH3VCPGNAO1HTR4 | |
| SCHEMBL24866029 | 0.81 | VCP (0.41) | HRH3VCPGNAO1 | |
| SCHEMBL22301687 | 0.81 | HRH3 (0.40) | HRH3VCPGNAO1 | |
| SCHEMBL24952354 | 0.80 | VCP (0.43) | HRH3VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | HRH3 3222/4885VCP 2270/4885GNAO1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.